Revenue Summary of InnoPharmax Inc.

InnoPharmax Inc.'s latest annual revenue in 2023 was 46.07 Million TWD , up 58.15% from previous year.
InnoPharmax Inc.'s latest quarterly revenue in 2024 Q2 was 11.58 Million TWD , down 0.0% from previous quarter.
InnoPharmax Inc. reported a annual revenue of 29.13 Million TWD in annual revenue 2022, down -39.38% from previous year.
InnoPharmax Inc. reported a annual revenue of 48.05 Million TWD in annual revenue 2021, down -64.89% from previous year.
InnoPharmax Inc. reported a quarterly revenue of 11.58 Million TWD for 2024 Q2, down 0.0% from previous quarter.
InnoPharmax Inc. reported a quarterly revenue of 17.32 Million TWD for 2023 Q2, down 0.0% from previous quarter.

Annual Revenue Chart of InnoPharmax Inc. (2023 - 2019)

Name	Revenue	Revenue Difference
Allied Biotech Corporation	720.43 Million TWD	93.605%
GeneFerm Biotechnology Co., Ltd.	793.77 Million TWD	94.196%
Easywell Biomedicals, Inc.	271.62 Million TWD	83.038%
TTY Biopharm Company Limited	5.5 Billion TWD	99.163%
Synmosa Biopharma Corporation	5.14 Billion TWD	99.104%
Orient EuroPharma Co., Ltd.	4.59 Billion TWD	98.997%
Center Laboratories, Inc.	1.39 Billion TWD	96.695%
Tien Liang BioTech Co., Ltd.	459.99 Million TWD	89.984%
Orient Pharma Co., Ltd.	889.91 Million TWD	94.823%
Johnson Chemical Pharmaceutical Works Co., Ltd.	606.71 Million TWD	92.406%
Excelsior Biopharma Inc.	771.56 Million TWD	94.029%
DV Biomed Co., Ltd.	1.53 Billion TWD	97.005%
Foresee Pharmaceuticals Co., Ltd.	195.03 Million TWD	76.377%
Handa Pharmaceuticals, Inc.	1.1 Billion TWD	95.835%
UniPharma Co., Ltd.	103.22 Million TWD	55.365%
Anxo Pharmaceutical Co., Ltd.	939.94 Million TWD	95.098%
Alar Pharmaceuticals Inc.	469.27 Million TWD	90.182%
Winston Medical Supply Co., Ltd.	709.07 Million TWD	93.502%
Mercury Biopharmaceutical Corporation	1.03 Million TWD	-4360.116%
Bioray Biotech Co., Ltd	191.83 Million TWD	75.982%
TSH Biopharm Corporation Limited	810.91 Million TWD	94.318%